Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CHRNA10 Biologics Sequence Review Report 2026: Neuronal acetylcholine receptor subunit alpha-10 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRNA10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHRNA3 Biologics Sequence Review Report 2026: Neuronal acetylcholine receptor subunit alpha-3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRNA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHRNA2 Biologics Sequence Review Report 2026: Neuronal acetylcholine receptor subunit alpha-2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRNA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHRNA1 Biologics Sequence Review Report 2026: Acetylcholine receptor subunit alpha Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRNA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHRM3 Biologics Sequence Review Report 2026: Muscarinic acetylcholine receptor M3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRM3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHRM2 Biologics Sequence Review Report 2026: Muscarinic acetylcholine receptor M2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRM2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHRM5 Biologics Sequence Review Report 2026: Muscarinic acetylcholine receptor M5 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRM5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHRM4 Biologics Sequence Review Report 2026: Muscarinic acetylcholine receptor M4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRM4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CFHR5 Biologics Sequence Review Report 2026: Complement factor H-related protein 5 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CFHR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CFHR4 Biologics Sequence Review Report 2026: Complement factor H-related protein 4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CFHR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CFHR3 Biologics Sequence Review Report 2026: Complement factor H-related protein 3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CFHR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CHRM1 Biologics Sequence Review Report 2026: Muscarinic acetylcholine receptor M1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CHRM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
49
50
51
52
53
>>
1620
>